Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic.
Work led by Dr Mark Blaskovich at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions, in collaboration with Botanix Pharmaceuticals Ltd, an early stage drug discovery company investigating topical uses of synthetic cannabidiol for a range of skin conditions, found that Cannabidiol was remarkably effective at killing a wide range of Gram-positive bacteria, including bacteria that have become resistant to other antibiotics, and did not lose effectiveness after extended treatment.
“Given cannabidiol’s documented anti-inflammatory effects, existing safety data in humans, and potential for
... read more at: https://www.sciencedaily.com/releases/2019/06/190623143055.htm